Introduction

Patients who do not receive thromboprophylaxis after an orthopedic surgery procedure will likely develop a deep venous thrombosis (DVT). The incidence of this complication is variable based on the type of procedure. In the absence of prophylaxis, as many as 86% of patients undergoing knee replacement will develop a DVT in the first day post-surgery. The incidence is somewhat lower with hip replacement; a 50% likelihood in the absence of thromboprophylaxis. Those with hip surgery experience an increased risk for up to 3 weeks after surgery. The risk of DVT stabilizes after 4 weeks in knee replacement and 10 weeks in hip replacement. Current commonly used agents for thromboembolism prophylaxis include unfractionated heparin (UFH) and low molecular weight heparin (LMWH).

Pharmacology/Pharmacokinetics

The site of action for fondaparinux is antithrombin III (ATIII) where the agent selectively binds and potentiates the neutralization of Factor Xa by ATIII. This results in a disruption of the coagulation cascade, inhibiting thrombus formation.

Fondaparinux is administered by subcutaneous injection with rapid and complete absorption. In patients receiving treatment, Cmax is achieved approximately 3 hours post dose. The drug is distributed in blood with only a small proportion going to the extravascular fluid. Steady state volume of distribution is 7-11L. Since fondaparinux is specific in binding to ATIII, there is negligible binding to plasma proteins or red blood cells. The elimination half-life for the drug is 17-21 hours. The primary route of elimination is urinary excretion of unchanged drug.

FDA Approved Indication(s) and Off-label Uses

Fondaparinux is indicated for the prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery, hip replacement surgery and knee replacement surgery. Prevention of DVT may prevent development of pulmonary embolism in these patients. The FDA approved the agent in 2001 with a 1-P rating.

Dosage and Administration

The recommended dose of fondaparinux is 2.5 mg given by subcutaneous injection once daily. The initial dose of medication is administered after postsurgical hemostasis is established, usually 6 to 8 hours after surgery. The medication is supplied as a prefilled injector, with explicit instructions for use.

Adverse Effects (Safety Data)

The most common adverse effects with fondaparinux treatment are bleeding complications. In knee replacement surgery, major bleeding, defined as clinically overt bleeding that was (1) fatal, (2) bleeding at critical site (e.g., intracranial, retroperitoneal, intra-ocular, pericardial, spinal or into adrenal gland), (3) associated with re-operation at operative site,
Fondaparinux sodium (Arixtra®)

or (4) with a bleeding index (BI) ≥2. BI ≥2: overt bleeding associated only with a bleeding index (BI) ≥2 [calculated as number of whole blood or packed red blood cells transfused + [(pre-bleeding) - (post-bleeding)] hemoglobin (g/dL) values was significantly greater in patients receiving fondaparinux than enoxaparin sodium-treated patients, 2.1% versus 0.2% respectively.

The rates of bleeding, both major and minor are described in Table 1.

**Table 1. Bleeding across Hip Fracture, Hip Replacement, and Knee Replacement Surgery Studies**

<table>
<thead>
<tr>
<th>Indications</th>
<th>Fondaparinux Sodium 2.5 mg SC once daily N = 3616</th>
<th>Comparator: Low Molecular Weight Heparin or Enoxaparin Sodium1 N = 3956</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Bleeding</td>
<td>96 (2.7%)</td>
<td>75 (1.9%)</td>
</tr>
<tr>
<td>Fatal Bleeding</td>
<td>0 (0.0%)</td>
<td>1 (&lt;0.1%)</td>
</tr>
<tr>
<td>Non-fatal bleeding at critical site</td>
<td>0 (0.0%)</td>
<td>1 (&lt;0.1%)</td>
</tr>
<tr>
<td>Re-operation due to bleeding</td>
<td>12 (0.3%)</td>
<td>10 (0.3%)</td>
</tr>
<tr>
<td>(BI) ≥2</td>
<td>84 (2.3%)</td>
<td>63 (1.6%)</td>
</tr>
<tr>
<td>Minor Bleeding4</td>
<td>109 (3.0%)</td>
<td>116 (2.9%)</td>
</tr>
</tbody>
</table>

Asymptomatic increases in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels greater than three times the upper limit of normal of the laboratory reference range have been reported. Such elevations are fully reversible and are rarely associated with increases in bilirubin.

**Other**

Other adverse events that occurred during clinical trials with patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery and that occurred at a rate of at least 2% in either treatment group, are provided in Table 2 below.

**Table 2. Adverse Events Occurring in ≥2% of ARIXTRA or Enoxaparin Sodium Treated Patients Regardless of Relationship to Study Drug Across Hip Fracture Surgery, Hip Replacement Surgery, or Knee Replacement Surgery Studies**

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Fondaparinux Sodium 2.5 mg SC once daily N = 3616</th>
<th>Comparator: Low Molecular Weight Heparin or Enoxaparin Sodium1 N = 3956</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>707 (19.6%)</td>
<td>670 (16.9%)</td>
</tr>
<tr>
<td>Fever</td>
<td>491 (13.6%)</td>
<td>610 (15.4%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>409 (11.3%)</td>
<td>484 (12.2%)</td>
</tr>
<tr>
<td>Edema</td>
<td>313 (8.7%)</td>
<td>348 (8.8%)</td>
</tr>
<tr>
<td>Constipation</td>
<td>309 (8.5%)</td>
<td>416 (10.5%)</td>
</tr>
<tr>
<td>Rash</td>
<td>273 (7.5%)</td>
<td>329 (8.3%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>212 (5.9%)</td>
<td>236 (6.0%)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>179 (5.0%)</td>
<td>214 (5.4%)</td>
</tr>
<tr>
<td>Wound drainage increased</td>
<td>161 (4.5%)</td>
<td>184 (4.7%)</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>152 (4.2%)</td>
<td>164 (4.1%)</td>
</tr>
</tbody>
</table>

April 2002
Updated versions may be found at http://www.vaphm.org or http://vaww.pbm.med.va.gov
Fondaparinux sodium (Arixtra®)

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Fondaparinux</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary tract infection</td>
<td>136 (3.8%)</td>
<td>135 (3.4%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>131 (3.6%)</td>
<td>165 (4.2%)</td>
</tr>
<tr>
<td>Purpura</td>
<td>128 (3.5%)</td>
<td>137 (3.5%)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>126 (3.5%)</td>
<td>125 (3.2%)</td>
</tr>
<tr>
<td>Confusion</td>
<td>113 (3.1%)</td>
<td>132 (3.3%)</td>
</tr>
<tr>
<td>Bullous eruption</td>
<td>112 (3.1%)</td>
<td>102 (2.6%)</td>
</tr>
<tr>
<td>Urinary retention</td>
<td>106 (2.9%)</td>
<td>117 (3.0%)</td>
</tr>
<tr>
<td>Hematoma</td>
<td>103 (2.8%)</td>
<td>109 (2.8%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>90 (2.5%)</td>
<td>102 (2.6%)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>87 (2.4%)</td>
<td>102 (2.6%)</td>
</tr>
<tr>
<td>Post-operative hemorrhage</td>
<td>85 (2.4%)</td>
<td>69 (1.7%)</td>
</tr>
<tr>
<td>Headache</td>
<td>72 (2.0%)</td>
<td>97 (2.5%)</td>
</tr>
<tr>
<td>Pain</td>
<td>62 (1.7%)</td>
<td>101 (2.6%)</td>
</tr>
</tbody>
</table>

1 Enoxaparin sodium dosing regimen: 30 mg every 12 hours or 40 mg once daily.

**Precautions/Contraindications**

Fondaparinux is contraindicated in patients with severely impaired kidney function or in patients who weigh less than 110 pounds, because they may have an increased risk for major bleeding. Patients greater than 75 years of age also may be more likely to experience major bleeding due to a 25% lower clearance of the agent. As with other antithrombotics, labeling for fondaparinux includes a boxed warning regarding use when spinal anesthesia or spinal puncture is used because of possible spinal/epidural hematomas.

**Drug Interactions**

The concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin has not been shown to significantly alter the pharmacokinetics/pharmacodynamics of fondaparinux sodium. In addition, the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam and digoxin, were not altered.

In an *in vitro* study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 µM i.e., 350 mg/L) was 17-28%. Inhibition of the other isozymes evaluated (CYPs 2A1, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0-16%. Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4) *in vitro*, fondaparinux sodium is not expected to significantly interact with other drugs *in vivo* by inhibition of metabolism mediated by these isozymes.

Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, no drug interactions by protein-binding displacement are expected.
Clinical Trials

Citation

Study Goals
To determine the efficacy of fondaparinux in thromboprophylaxis after hip fracture surgery.

Methods

- **Study Design**
  - Multicenter, randomized, double blind
  - N=1711 across 99 centers and 21 countries (no United States sites)
  - Day 1 was day of surgery, treatment continued for 5-9 days
  - Primary outcome, assessed at day 5-11
  - Followup between day 35-49
  - Primary outcome-incidence of venous thromboembolism up to day 11
  - Bilateral venography was mandatory
  - Fondaparinux 2.5 mg SQ daily, enoxaparin 40 mg SQ daily

- **Data Analysis**
  - A 22% incidence of VTE by day 11 was assumed
  - A risk reduction of 30% was anticipated, power was 85%

Criteria

- **Inclusion criteria**
  - At least 18 years of age
  - Standard surgery for fracture of the upper third of the femur within 48 hours of admission

- **Exclusion criteria**
  - Serum creatinine ≥ 2 mg/dl
  - Platelet count < 100,000/mm³
  - Multiple trauma
  - Greater than 24 hours between injury and hospital admission
  - Pregnancy
  - Active bleeding
  - History of congenital or acquired bleeding disorder
  - History of hemorrhagic stroke or brain, spinal, ophthalmologic surgery in previous 3 months
  - Planned use of indwelling epidural catheter

Results

<table>
<thead>
<tr>
<th>Efficacy Measure</th>
<th>Fondaparinux</th>
<th>Enoxaparin</th>
<th>ARR</th>
<th>NNT</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of VTE by day 11</td>
<td>52/626(8.3%)</td>
<td>119/624(19.1%)</td>
<td>10.8%</td>
<td>10</td>
<td>15.3-6.6%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Treated by physician for VTE by day 11</td>
<td>43/702(6.1%)</td>
<td>84/716(11.7%)</td>
<td>5.6%</td>
<td>20</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Any deep vein thrombosis</td>
<td>49/624(7.9%)</td>
<td>117/623(18.8%)</td>
<td>10.9%</td>
<td>10</td>
<td>15.4-6.8%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Symptomatic VTE</td>
<td>4/831(0.5%)</td>
<td>4/840(0.5%)</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Safety Outcome</th>
<th>Fondaparinux (N=831)</th>
<th>Enoxaparin (N=842)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major bleed</td>
<td>18</td>
<td>19</td>
<td>1.00</td>
</tr>
<tr>
<td>Minor bleed</td>
<td>34</td>
<td>18</td>
<td>0.02</td>
</tr>
<tr>
<td>Mean number units transfused</td>
<td>2.7±1.5</td>
<td>2.8±1.8</td>
<td></td>
</tr>
<tr>
<td>Death from any cause</td>
<td>11</td>
<td>16</td>
<td></td>
</tr>
</tbody>
</table>

Major bleeding was defined as clinically overt bleeding that was (1) fatal, (2) bleeding at critical site (e.g., intracranial, retroperitoneal, intra-ocular, pericardial, spinal or into adrenal gland), (3) associated with re-operation at operative site, or (4) with a bleeding index (BI) ≥2. BI ≥2: overt bleeding associated only with a bleeding index (BI) ≥2 [calculated as number of whole blood or packed red blood cells transfused + [pre-bleeding] - [post-bleeding] hemoglobin (g/dL) values].
### Conclusions

Fondaparinux was more effective than enoxaparin 40 mg daily in preventing venous thromboembolism. The agents were equally safe, with no significant differences in major and minor bleeding.

### Critique

**Strengths**
- Defined outcome measure followed with bilateral venography
- Large study size with multiple centers and investigators
- Use of bleeding index to account for patients with lower hemoglobin levels prior to study

**Limitations**
- A steering committee composed of 10 people (6 representatives from the pharmaceutical sponsor) designed, interpreted and authored the manuscript of the trial.
- No US centers in trial
- No clear definition of when treatment was to end
- No set protocol to treat VTE
- Duration of treatment may have been too short for high risk patients
- Low incidence of pulmonary embolism may have been influenced by early venography

### Citation


### Study Goals

To determine the efficacy of fondaparinux in thromboprophylaxis after knee surgery.

### Methods

**Study Design**
- Multicenter, randomized, double blind
- N=1049 across 64 centers in North America
- Day 1 was day of surgery, treatment continued for 5-9 days
- Primary outcome, assessed at day 5-11
- Followup between day 35-49
- Primary outcome-incidence of venous thromboembolism up to day 11
- Bilateral venography was mandatory
- Fondaparinux 2.5 mg SQ daily, enoxaparin 30 mg SQ twice daily

**Data Analysis**
- Incidence of VTE assumed to be 34%, anticipated risk reduction 30%
- Power 85%

### Criteria

**Inclusion criteria**
- At least 18 years of age
- Elective major knee surgery defined as resection of the distal end of the femur or proximal end of the tibia or a revision of at least one component of previously implanted total knee prosthesis.

**Exclusion criteria**
- Serum creatinine > 2 mg/dl
- Platelet count < 100,000/mm³
- Multiple trauma
- Greater than 24 hours between injury and hospital admission
- Pregnancy
- Active bleeding
- History of congenital or acquired bleeding disorder
- History of hemorrhagic stroke or brain, spinal, ophthalmologic surgery in previous 3 months
- Planned use of indwelling epidural catheter
- Surgery in contralateral knee was simultaneous or planned within 2 weeks

April 2002

Updated versions may be found at http://www.vaphm.org or http://vaww.pbm.med.va.gov

5
Fondaparinux sodium (Arixtra®)

**Results**

<table>
<thead>
<tr>
<th>Efficacy Measure</th>
<th>Fondaparinux</th>
<th>Enoxaparin</th>
<th>ARR %</th>
<th>NNT</th>
<th>95%CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of VTE by day 11</td>
<td>45/361(12.5%)</td>
<td>101/363(27.8%)</td>
<td>15.3%</td>
<td>6</td>
<td>22.3-9.3%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Any deep vein thrombosis</td>
<td>45/361(12.5%)</td>
<td>98/361(27.1%)</td>
<td>14.6%</td>
<td>7</td>
<td>21.4-8.4%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Symptomatic VTE</td>
<td>3/517(0.6%)</td>
<td>7/517(1.4%)</td>
<td>0.8%</td>
<td>-3.3-1.1%</td>
<td>0.34</td>
<td></td>
</tr>
</tbody>
</table>

**Safety Outcome**

<table>
<thead>
<tr>
<th></th>
<th>Fondaparinux (N=517)</th>
<th>Enoxaparin (N=517)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major bleed</td>
<td>11</td>
<td>1</td>
<td>0.006</td>
</tr>
<tr>
<td>Minor bleed</td>
<td>14</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Mean number units transfused</td>
<td>1.9±1.1</td>
<td>1.8±0.9</td>
<td></td>
</tr>
<tr>
<td>Death from any cause</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

Major bleeding was defined as clinically overt bleeding that was (1) fatal, (2) bleeding at critical site (e.g., intracranial, retroperitoneal, intra-ocular, pericardial, spinal or into adrenal gland), (3) associated with re-operation at operative site, or (4) with a bleeding index (BI) ≥2. BI ≥2: overt bleeding associated only with a bleeding index (BI) ≥2 ([calculated as number of whole blood or packed red blood cells transfused + [(pre-bleeding) - (post-bleeding)] hemoglobin (g/dL) values].

**Conclusions**

Treatment with fondaparinux was more effective than treatment with enoxaparin for VTE prophylaxis in elective major knee surgery. There was no difference in the prevention of proximal DVT in the two treatment groups. The incidence of major bleeding was significantly more with fondaparinux treatment.

**Critique**

- **Strengths**
  - Defined outcome measure followed with bilateral venography
  - Large study size with multiple centers and investigators
  - Use of bleeding index to account for patients with lower hemoglobin levels prior to study
- **Limitations**
  - A steering committee composed of 10 people (7 representatives from the pharmaceutical sponsor) designed, interpreted and authored the manuscript of the trial.
  - No clear definition of when treatment was to end
  - No set protocol to treat VTE
  - Duration of treatment may have been too short for high risk patients
  - Low incidence of pulmonary embolism may have been influenced by early venography

**Acquisition Costs**

**Elective major knee surgery**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Cost/Day/patient ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fondaparinux</td>
<td>2.5 mg QD</td>
<td>26.05</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>30 mg BID</td>
<td>18.52</td>
</tr>
</tbody>
</table>

**Hip Fracture repair surgery**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Cost/Day/patient ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fondaparinux</td>
<td>2.5 mg QD</td>
<td>26.05</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>40 mg QD</td>
<td>12.85</td>
</tr>
</tbody>
</table>

April 2002

Updated versions may be found at http://www.vaphm.org or http://vaww.pbm.med.va.gov
Conclusions

The mechanism of action for fondaparinux provides a unique method of inhibiting the coagulation pathway. Given the specific binding of this agent it may provide benefit over currently available agents. The clinical trials conducted with this agent have shown superiority to the doses of enoxaparin used. However, fondaparinux showed a significant increase in the episodes of major bleeding in the knee surgery trial.

There are concerns regarding the use of fondaparinux in elderly patients and in those with decreased renal function. The drug interaction profile of the agent appears minimal with commonly employed agents.

Once daily dosing of fondaparinux offers advantages, as does the use of a prefilled syringe.

Recommendations

Fondaparinux sodium should remain non-formulary. Presently the only information available is in knee and hip surgery with trials in unstable angina, treatment of DVT/PE and trauma/surgery prophylaxis of VTE underway. There is a significant cost difference between fondaparinux and enoxaparin. Additionally, the concern of using this agent in patients over 75 years and with compromised renal function may impact a large proportion of VA patients. Fondaparinux would remain an option for patients with allergy to LMWH products.

Prepared by: Kathryn Tortorice, PharmD, BCPS
Date: April 2002
National PBM Drug Monograph Addendum  
Fondaparinux (Arixtra®)  
VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel

Please see the original drug monograph at:  
http://vaww.pbm.med.va.gov/drugmonograph/fondaparinuxreview.pdf

Introduction

Since the approval of fondaparinux in December 2001 and the subsequent monograph review in 2002,  
several clinical trials have investigated the use of fondaparinux in other thrombotic conditions such as  
pulmonary embolism, symptomatic deep vein thrombosis and orthopedic procedures. Additionally Phase II  
and III trials are investigating its use in acute coronary syndrome, ST elevation MI and venous  
thromboembolism. Trials investigating the duration of thromboembolism prophylaxis with fondaparinux as  
well as economic variables have been conducted.

These trials may hold findings that could impact the formulary status of the agent or suggest that criteria for  
use be developed for the agent.

Pulmonary Embolism

The standard of care for acute pulmonary embolism (PE) has involved hospitalization and initiation of  
systemic anticoagulation with unfractionated heparin (UFH). This therapy requires frequent laboratory  
monitoring and dose adjustments. Fondaparinux offers the advantage of once daily injection and no  
laboratory monitoring. The Matisse Investigators\(^1\) undertook an open label trial of fondaparinux versus  
standard therapy in 2213 patients with acute, symptomatic PE. The dose of fondaparinux was weight  
adjusted, 5.0 mg, 7.5 mg, 10 mg for body weights of <50 kg, 50-100 kg and >100 kg, respectively. UFH  
therapy maintained an activated partial thromboplastin time of 1.5-2.5 times control. The primary efficacy  
outcome was symptomatic recurrent venous thromboembolism during the three-month study period. This  
was defined as occurring if patients developed objective evidence of recurrent PE or deep vein thrombosis  
or if death from PE could not be ruled out. For the primary outcome, fondaparinux demonstrated recurrence  
in 3.8%, UFH in 5.0% (absolute risk reduction −1.2, 95% CI −3 to 0.5). This translates to a NNT of 83. In  
terms of adverse effects, the incidence of major bleeding during initial treatment in the fondaparinux group  
was 1.3%, UFH 1.1% (absolute risk reduction 0.2%, 95%CI −0.7 to 1.1). This translates to an NNH of 5.

This trial demonstrated that fondaparinux and enoxaparin have a similar safety and efficacy profile in the  
treatment of PE.

In June 2004, fondaparinux received FDA approval for the treatment of PE.

Symptomatic Deep Venous Thrombosis

In June 2004, the results of the fondaparinux versus enoxaparin in the initial treatment of symptomatic VTE  
conducted by the Matisse Investigators were published\(^2\). This trial was conducted worldwide and involved  
2205 patients with acute, symptomatic VTE. The dose of fondaparinux was weight adjusted, 5.0 mg, 7.5  
mg, 10 mg for body weights of <50 kg, 50-100 kg and >100 kg, respectively. Enoxaparin was dosed at  
1 mg/kg twice daily. Both agents were given for at least 5 days and until vitamin K antagonists achieved an  
international normalized ratio greater than 2.0. The primary study outcome was the 3-month incidence of  
symptomatic, recurrent VTE. The development of the primary outcome occurred in 3.9% of fondaparinux  
treated patients versus 4.1% of enoxaparin treated patients (95% CI −1.8 to 1.5, NNT=5). There was no  
significant difference in the development of major bleeding between the two groups (fondaparinux 1.1%,  
exoxaparin 1.2%).

In June 2004, fondaparinux received FDA approval for the treatment of VTE.

July 2004
Updated versions may be found at http://www.vapbm.org or http://vaww.pbm.med.va.gov
Fondaparinux- Monograph Addendum

Prophylaxis in Major Orthopedic Surgery

The pivotal trials for approval of fondaparinux involved patients undergoing knee replacement surgery and hip fracture surgery (PENTAMAKS1 and PENTHIFRA4, respectively). Subsequently, two trials have investigated the use of fondaparinux in elective hip surgery (EPHESUS5) and in total hip replacement (PENTATHLON 20006). The EPHESUS trial was conducted in Europe and utilized an enoxaparin dose of 40 mg daily. The primary efficacy outcome for this trial was venous thromboembolism (deep vein thrombosis, pulmonary embolism or both) measured at day 11. The absolute risk reduction was 5% (95% CI 8.1%-2.7%, p<0.0001) for fondaparinux versus enoxaparin correlating to an NNT of 20. The number of neither patients with major bleeding nor those with a bleeding index >2 were different between the two treatment groups (<1% in both groups and 4% versus 3% for fondaparinux, enoxaparin respectively). The PENTATHALON 2000 trial was the North American counterpart of the previous trial. This trail used fondaparinux at the same dose as in EPHESUS (2.5 mg daily) but enoxaparin was dosed at 30 mg twice daily. The absolute risk reduction in this trial was 2% (95% CI 5.5% to 0.6%, p=0.099) and NNT 50. Safety outcomes of this trial were the same as the previous trial, the two groups did not differ significantly in terms of major bleeding or patients with a bleeding index of >2.

Turpie, et al, conducted a meta-analysis7 of these four orthopedic prophylaxis trials.7 They found no difference between the groups in terms of age, weight, previous venous thromboembolism and previous orthopedic surgery. There were 3616 patients in the fondaparinux group and 3621 in the enoxaparin group. It should be remembered that differing doses of enoxaparin were used in these trials dependent on location of the trial (Europe versus North America). The fondaparinux treated group developed venous thromboembolism by day 11 in 182 of 2682 patients and the enoxaparin group in 371 of 2703 patients. This results in a common odds reduction of 55.2% (95% CI 45.8% to 63.1%, p<0.001). The incidence of clinically significant bleeding did not differ between the groups.

These trials demonstrate fondaparinux to have greater efficacy than enoxaparin in regards to VTE prophylaxis after major orthopedic surgery. Currently, low molecular weight heparin (LMWH) has a Grade 1A recommendation from the American College of Chest Physicians (2001) for elective hip and knee replacement. The use of LMWH in hip fracture has a grade 1B recommendation. Since fondaparinux has shown greater efficacy with equivalent safety to enoxaparin in PENTHIFRA, it may be deemed a reasonable alternative in hip fracture prophylaxis. The update of the ACCP recommendations is due to be released in the summer of 2004.

Duration of Prophylaxis

Eriksson, et al.8 demonstrated the benefit of fondaparinux versus placebo for 1 month after hip fracture surgery. In this trial patients received fondaparinux 2.5 mg daily for 6-8 days after surgery and were then randomized to receive placebo or continue with their current regimen. The primary outcome was venous thromboembolism (deep vein thrombosis, pulmonary embolism or both) measured at day 25 to 32. The absolute risk reduction for fondaparinux versus placebo was 33.6% (95% CI 41.4% to 26.5%, p<0.001). This correlates to an NNT of 3. The utility of extended prophylaxis with LMWH has been defined in earlier trials9,10.

Cost Effectiveness Evaluations

Incremental cost analysis based on clinical trial results has been conducted with fondaparinux. These studies have been conducted on the major clinical trials of Fondaparinux in orthopedic indications. The economic trials have been conducted from a healthcare payer standpoint and involved only direct costs. A cost effectiveness study based on the Bauer, et al trial compared fondaparinux to enoxaparin.11 This trial involved VTE prophylaxis in knee surgery and compared fondaparinux 2.5 mg daily for 5 days to enoxaparitin 30 mg twice daily for 4 days. The analysis showed a $1081.33 cost savings for fondaparinux per VTE avoided. In contrast, a cost effectiveness analysis of the Eriksson, et al. trial for VTE prophylaxis in hip fracture demonstrates that costs of $573.20 would be incurred if fondaparinux were utilized in place of enoxaparin.12 Both of the cost effectiveness trials were conducted post hoc, employed adverse event rate, doses and outcomes from the pivotal trials and came to conflicting conclusions.
Sullivan, et al. have conducted a cohort simulation model of a 7 day prophylactic regimen with either fondaparinux or enoxaparin which subsequently followed patients for 30 days, 90 days and 5 years post discharge. The use of fondaparinux was associated with a cost saving of $2, $76, $100 at discharge, 1 month, and 3 months respectively. This was seen across all treatment types but most robust with the use in hip fracture surgery.

The trials from Turpie, et al. and Lassen, et al. were the basis for a cost effectiveness analysis which demonstrated that fondaparinux could produce savings of $6612.11 per VTE avoided in comparison to enoxaparin 40 mg once daily. However, the use of enoxaparin 30 mg twice daily demonstrated a cost savings of $50,171.89 per VTE avoided. This analysis was limited to proximal VTE and non fatal PE. The design did factor in the associated bleeding rates from the studies.

**Ongoing trials**

Several trials are currently underway regarding the use of fondaparinux for conditions such as medical indications (ARTEMIS), acute coronary syndrome and VTE prophylaxis in abdominal surgery (PEGASUS fondaparinux versus dalteparin). These trials will help to answer remaining questions regarding the place in therapy for this agent.

**Conclusion**

Fondaparinux administered 6-8 hours after surgery has demonstrated greater or equivalent efficacy to enoxaparin in VTE prophylaxis for major orthopedic procedures. The use of fondaparinux in the treatment of symptomatic VTE has demonstrated equivalent safety and efficacy to twice daily enoxaparin. The use of fondaparinux has demonstrated equivalent efficacy to UFH in the treatment of PE. Additionally, the safety profile is equivalent with no increase in major or minor bleeding over the LMWH preparation. There have been several cost effectiveness analysis based on the outcomes of these clinical trials. The results of these trials do not consistently demonstrate fondaparinux to be more cost effective. They have displayed a possible association with enoxaparin dose used as comparator as well as surgery type. Further analysis is required to demonstrate a consistent outcome.

**Current Prices**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>FSS price</th>
<th>Cost per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dalteparin</td>
<td>2500 units</td>
<td>$7.64*</td>
<td>$7.64*</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>5000 units</td>
<td>$12.37*</td>
<td>$12.37*</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>30 mg</td>
<td>$8.90</td>
<td>$17.80</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>40 mg</td>
<td>$12.08</td>
<td>$12.08</td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>2.5 mg</td>
<td>$18.09</td>
<td>$18.09</td>
</tr>
</tbody>
</table>

*BIG4 pricing not FSS

These prices are current as of 5/3/04. To determine current prices after this date please refer to our website at vawww.pbm.med.va.gov.

July 2004
Updated versions may be found at http://www.vapbm.org or http://vawww.pbm.med.va.gov
References